Key Highlights

● Net sales rose 3.2% to $3.886 billion, with organic growth of 2.9%.

● Adjusted EPS was $0.29 against $0.28 a year earlier.

● The company offered no guidance and held no call because the Merger is pending.

● Self Care led segments, with sales up 5.9% and Tylenol gaining U.S. share.

The third-quarter report from Kenvue (NYSE:KVUE) reads less like a normal Earnings release and more like a final progress report before a merger. The maker of Tylenol, Listerine, Neutrogena and Band-Aid released results at 6:45 a.m. ET Friday. It offered no guidance and held no conference call, because its combination with Kimberly-Clark is pending.

A confirmed pre-market price move for Kenvue was not available, so its direction before the open is unclear. One morning note listed Kenvue's earnings as flat against expectations. Its acquirer is moving, though: Kimberly-Clark was up 2.81% at $113.11 in a pre-market table as of 8:23 a.m. ET.

A quiet but solid quarter

Net sales rose 3.2% to $3.886 billion, and Organic Sales grew 2.9%, split between 1.6% Volume growth and 1.3% from price and mix, according to the company's release. Adjusted EPS was $0.29, compared with $0.28 a year earlier, and GAAP EPS was $0.22. Adjusted Operating Margin was 21.9%.

CEO Kirk Perry said the company was "pleased to have delivered our fourth consecutive quarter of net and organic sales growth." He also pointed to the deal directly: "As we near the completion of our value-creating combination with Kimberly-Clark."

Self Care was the strongest segment, with sales up 5.9% to $1.66 billion and organic growth of 5.4%. The release said Tylenol gained U.S. market share. Essential Health, which includes Listerine and Johnson's Baby, grew 2.5% to $1.19 billion. Skin Health and Beauty, home to Neutrogena and Aveeno, was flat at $1.04 billion, with organic sales down 0.5%, as distribution losses and promotion timing offset strong growth in Hair Care.

Over nine months, Kenvue generated $1.6 billion in free cash flow, up from $1.0 billion a year earlier, and cut total Debt to $8.2 billion from $8.5 billion at the end of 2025.

Why the numbers matter less than the deal

"Due to the pending transaction with Kimberly-Clark, the Company will not be providing forward-looking guidance," the release said. That leaves investors with little new information about Kenvue's standalone future, because its shares are now largely tied to the terms and timing of the merger.

The release didn't give a closing date or deal terms. Automated market notes described the deal as a $48.7 billion Acquisition and said Kimberly-Clark had closed a $4.9 billion notes offering to help fund it. Those details come from an automated summary, so they should be treated as reported rather than confirmed.

For merger investors, a steady quarter is mostly reassuring. It suggests the Business is not weakening before the handover, which reduces the risk of last-minute problems.

S&P 500 context and what to watch

Kenvue is an S&P 500 member. Once the deal closes, it would be expected to leave the index as a standalone company, a common outcome when a member is acquired, although S&P Dow Jones Indices has not announced any change.

Consumer staples are drawing interest on Friday. Colgate-Palmolive (NYSE:CL) and Church & Dwight (NYSE:CHD) were both up more than 4% pre-market after strong results, while Nasdaq-100 futures were down about 2.5% on AI spending worries tied to Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC). Kenvue's merger structure makes it less sensitive to that rotation than standalone peers.

The main risks are regulatory or legal delays to the deal, any change in terms, and continued weakness in Skin Health and Beauty. At and after the open, watch Kenvue's price relative to Kimberly-Clark's for signs of how confident traders are in the deal closing, and watch for any announcement of a closing date or index changes.